Skip to main content

More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study

Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.